Homo sapiens
Ontology highlight
ABSTRACT:
PROVIDER: PRJNA98557 | ENA |
REPOSITORIES: ENA
Similar Datasets
Project description:Breast cancers contain a minority population of cancer cells characterized by CD44 expression but low or undetectable levels of CD24 (CD44+CD24-/low) that have higher tumorigenic capacity than other subtypes of cancer cells. METHODS: We compared the gene-expression profile of CD44+CD24-/low tumorigenic breast-cancer cells with that of normal breast epithelium. Differentially expressed genes were used to generate a 186-gene invasiveness gene signature (IGS), which was evaluated for its association with overall survival and metastasis-free survival in patients with breast cancer or other types of cancer. RESULTS: There was a significant association between the IGS and both overall and metastasis-free survival (P<0.001, for both) in patients with breast cancer, which was independent of established clinical and pathological variables. When combined with the prognostic criteria of the National Institutes of Health, the IGS was used to stratify patients with high-risk early breast cancer into prognostic categories (good or poor); among patients with a good prognosis, the 10-year rate of metastasis-free survival was 81%, and among those with a poor prognosis, it was 57%. The IGS was also associated with the prognosis in medulloblastoma (P=0.004), lung cancer (P=0.03), and prostate cancer (P=0.01). The prognostic power of the IGS was increased when combined with the wound-response (WR) signature. CONCLUSIONS: The IGS is strongly associated with metastasis-free survival and overall survival for four different types of tumors. This genetic signature of tumorigenic breast-cancer cells was even more strongly associated with clinical outcomes when combined with the WR signature in breast cancer. Expression profling was performed on 6 tumorigenic, 3 non tumorigenic samples of breast tumors and 3 normal breast samples on two different platforms GPL96 and GPL97. A gene signature was derived by comparing the gene expressions of 6 tumorigenic samples with 3 normal breast samples.
2007-11-02 | E-GEOD-6883 | biostudies-arrayexpress
Project description:Prognostic signature of epithelial-mesenchymal transition in breast cancer
| PRJNA110335 | ENA
Project description:HMGA1 is a well-established oncogene and is a master regulator in breast cancer cells controlling the shift from a non-tumorigenic epithelial-like phenotype towards a highly aggressive mesenchymal-like one. In this work we compared HMGA1-silenced versus control MDA-MB-231 by means of a label free shotgun proteomics approach and crossed these data with DNA microarray expression profile obtained on the same cells. Resulting data were then filtered for genes linked to poor prognosis in breast cancer gene expression meta-datasets. This workflow allows us to establish a small molecular signature composed by 21 members with a prognostic value as regards overall-, recurrence free-, and distant metastasis free-survival in breast cancer.
2018-10-17 | PXD002032 | Pride
Project description:Breast cancers contain a minority population of cancer cells characterized by CD44 expression but low or undetectable levels of CD24 (CD44+CD24-/low) that have higher tumorigenic capacity than other subtypes of cancer cells. METHODS: We compared the gene-expression profile of CD44+CD24-/low tumorigenic breast-cancer cells with that of normal breast epithelium. Differentially expressed genes were used to generate a 186-gene invasiveness gene signature (IGS), which was evaluated for its association with overall survival and metastasis-free survival in patients with breast cancer or other types of cancer. RESULTS: There was a significant association between the IGS and both overall and metastasis-free survival (P<0.001, for both) in patients with breast cancer, which was independent of established clinical and pathological variables. When combined with the prognostic criteria of the National Institutes of Health, the IGS was used to stratify patients with high-risk early breast cancer into prognostic categories (good or poor); among patients with a good prognosis, the 10-year rate of metastasis-free survival was 81%, and among those with a poor prognosis, it was 57%. The IGS was also associated with the prognosis in medulloblastoma (P=0.004), lung cancer (P=0.03), and prostate cancer (P=0.01). The prognostic power of the IGS was increased when combined with the wound-response (WR) signature. CONCLUSIONS: The IGS is strongly associated with metastasis-free survival and overall survival for four different types of tumors. This genetic signature of tumorigenic breast-cancer cells was even more strongly associated with clinical outcomes when combined with the WR signature in breast cancer. Keywords: cell type comparison
2007-03-10 | GSE6883 | GEO
Project description:A gene expression signature identifies two prognostic subgroups of basal breast cancer
| PRJNA125879 | ENA
Project description:Pivotal role of HMGA1 gene signature in highly metastatic breast cancer
| PRJNA152247 | ENA
Project description:A predictive and prognostic 38-gene expression signature for metastatic relapse in breast cancer
| PRJNA106779 | ENA
Project description:5-aza treatment of breast cancer and non-tumorigenic breast cells
| PRJNA291042 | ENA
Project description:The role of cancer exosomes in non-tumorigenic cells
| PRJNA259428 | ENA
Project description:Development of a prognostic gene signature in pancreatic cancer
| PRJNA246550 | ENA